Stoke Therapeutics, Inc. (STOK) - Dilution Analysis

Visualizing historical and potential share dilution over time

View Stock Details

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Dilution Analysis

High Risk

Significant dilution risk

Last updated: May 07, 2026

Risk Assessment Details

Potential Dilution: 58.22% of current shares

Recent Dilution: 30.02% (2 years)

Historical Dilution Factor: significant recent dilution

Outstanding Shares

63M

Potential Supply

37M

Additional shares possible

Splits

None

Past 2 years

Summary

STOK currently has 63.1M outstanding shares. with significant dilution risk as 36.7M authorized shares could dilute existing holders by 58.2%. The company has significantly diluted shareholders by 30.02% over the past 2 years, indicating aggressive capital raising.

Share Structure Timeline

Outstanding Shares

Total Supply

Historical Data Points

Date	Event	Outstanding	Supply
May 07, 2026	10-Q filing \| 63.1M shares outstanding	63M	37M
Mar 16, 2026	10-K filing \| 59.2M shares outstanding	59M	41M
Nov 04, 2025	10-Q filing \| 58.6M shares outstanding	59M	41M
Aug 12, 2025	10-Q filing \| 58.4M shares outstanding	58M	41M
Jul 09, 2025	S-3 filing: Stoke Therapeutics files an S-3 to offer common stock, preferred stock, debt securities, warrants, subscription rights and units for up to $400,000,000.	55M	45M
May 13, 2025	10-Q filing \| 57.9M shares outstanding	58M	21M
Mar 18, 2025	10-K filing \| 54.0M shares outstanding	54M	24M
Nov 05, 2024	10-Q filing \| 56.3M shares outstanding	56M	22M
Aug 07, 2024	10-Q filing \| 55.8M shares outstanding	56M	23M
Jun 13, 2024	S-3 filing: Registration for potential offer and sale from time to time of up to 10,843,681 shares of common stock by selling stockholders.	52M	26M
May 06, 2024	10-Q filing \| 52.1M shares outstanding	52M	15M
Mar 25, 2024	10-K filing \| 44.0M shares outstanding	44M	24M
Nov 07, 2023	10-Q filing \| 44.3M shares outstanding	44M	23M
Aug 07, 2023	10-Q filing \| 44.2M shares outstanding	44M	23M
May 04, 2023	10-Q filing \| 42.5M shares outstanding	43M	25M
Mar 06, 2023	10-K filing \| 44.1M shares outstanding	44M	23M
Nov 14, 2022	10-Q filing \| 39.4M shares outstanding	39M	28M
Aug 08, 2022	10-Q filing \| 39.3M shares outstanding	39M	28M
May 20, 2022	S-3 filing: Stoke Therapeutics, Inc. may offer up to $400,000,000 aggregate dollar amount of shares of its common stock or preferred stock, debt securities, warrants to purchase its common stock, preferred stock or debt securities, subscription rights to purchase its common stock, preferred stock or debt securities and/or units consisting of some or all of these securities.	39M	29M
May 10, 2022	10-Q filing \| 39.2M shares outstanding	39M	190K
Mar 10, 2022	10-K filing \| 37.4M shares outstanding	37M	2M
Nov 08, 2021	10-Q filing \| 36.8M shares outstanding	37M	2.6M
Aug 10, 2021	10-Q filing \| 36.7M shares outstanding	37M	2.6M
May 10, 2021	10-Q filing \| 36.7M shares outstanding	37M	2.7M
Mar 09, 2021	10-K filing \| 36.7M shares outstanding	37M	2.7M
Nov 12, 2020	10-Q filing \| 33.5M shares outstanding	33M	5.9M
Aug 10, 2020	10-Q filing \| 33.2M shares outstanding	33M	6.1M
Jul 10, 2020	S-3 filing: Stoke Therapeutics, Inc. files an S-3 to offer shares of common stock, preferred stock, debt securities, warrants, subscription rights and units, with a total proposed amount of $400,000,000.	33M	6.4M
May 15, 2020	10-Q filing \| 33.0M shares outstanding	33M	0
Mar 23, 2020	10-K filing \| 32.9M shares outstanding	33M	0

Back to STOK Details